International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 9 Issue 2, Mar-Apr 2025 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

A Review on Autism Spectrum Disorder: Advances in Neurobiology, Diagnosis, and Emerging Therapeutic Strategies

Vishal Kumar[1], Ms. Roshan Zehra[2]

[1]M. Pharma Student, [2]Assistant Professor,
[1,2]Innovative College of Pharmacy, Greater Noida, Uttar Pradesh, India

ABSTRACT

Repetitive behaviors, limited interests, and ongoing social communication impairments are hallmarks of autism spectrum disorder (ASD), a complex and diverse neurodevelopmental disorder. Although evidence suggests a multifaceted genesis combining genetic, epigenetic, neurological, and environmental variables, the precise etiology of ASD is still unknown. The pathogenesis of the condition has been influenced by developments in neurobiology, which have shown anomalies in immune system function, neurotransmitter control, and brain connectivity.

Behavioral tests like the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R) are used in traditional ASD diagnosis. To improve diagnostic accuracy, AI-driven models that include facial recognition, speech analysis, and eye tracking are being created. Behavioral interventions (Applied Behavior Analysis, Cognitive Behavioral Therapy), pharmaceutical techniques (antipsychotics, oxytocin-based therapies), and supportive therapies (occupational therapy, speech therapy) are examples of contemporary therapeutic approaches. Precision medicine, microbiome-targeted therapies, and neurotechnological developments (such virtual reality-based social training and transcranial magnetic stimulation) have all emerged as viable approaches to managing ASD in recent years.

KEYWORDS: *Autism Spectrum Disorder, Neurobiology, Genetic and Epigenetic Factors, Biomarkers, Artificial Intelligence, Early Diagnosis, Precision Medicine, Gut-Brain Axis, Behavioral Therapy, Neuroimaging, Neuromodulation, Microbiome-Based Therapies, Transcranial Magnetic Stimulation, Digital Therapeutics, Neurodevelopmental Disorders*

How to cite this paper: Vishal Kumar | Ms. Roshan Zehra "A Review on Autism Spectrum Disorder: Advances in Neurobiology, Diagnosis, and Emerging Therapeutic Strategies" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-9 | Issue-2, April 2025, pp.584-589, URL: www.ijtsrd.com/papers/ijtsrd78367.pdf

IJTSRD78367

1. INTRODUCTION

The complex neurological disorder known as autism spectrum disorder (ASD) is typified by repetitive behaviors, limited interests, and ongoing difficulties with social communication. People with different cognitive and linguistic capacities are affected in a wide range of severity. The World Health Organization (WHO) estimates that 1 in 100 children worldwide have an ASD diagnosis, and that prevalence is rising as a result of increased awareness and diagnostic tools.

The precise cause of ASD is still unknown despite much investigation. Research indicates that its development is influenced by a mix of environmental, genetic, and epigenetic variables. The fundamental underpinnings of ASD have been clarified by developments in neurobiology, which have identified anomalies in immune system function, neurotransmitter transmission, and brain connectivity. Additionally, new research emphasizes the gut-brain axis and suggests that microbial imbalances may affect behavior and neurodevelopment. The primary method of diagnosing ASD is behavioral evaluations using established criteria (DSM-5, ICD-11). Recent developments in biomarker identification, AI-powered instruments, and neuroimaging methods, however, present encouraging paths for earlier and

more precise diagnosis. Precision medicine, digital interventions, and microbiome-targeted therapeutics are examples of how therapeutic approaches have changed from conventional behavioral and pharmaceutical approaches.

This review aims to explore the latest developments in the neurobiological basis, diagnostic advancements, and innovative therapeutic strategies for ASD, providing insights into current challenges and future research directions. Understanding these complexities is essential for improving early intervention, personalized treatment, and overall quality of life for individuals with ASD.

Research and therapeutic therapy of autism spectrum disorder (ASD) are significantly hampered by its heterogeneity. ASD involves a wide spectrum of cognitive, behavioral, and sensory impairments, therefore no two people with the illness have exactly the same symptoms. Under earlier classification systems, high-functioning autism or Asperger's syndrome were terms used to describe people who showed exceptional talents in certain fields and high intelligence, while others may have substantial intellectual difficulties and limited verbal communication. The necessity for individualized methods to diagnosis and intervention is highlighted by this heterogeneity.

The Rising Prevalence and Societal Impact.

The reported prevalence of ASD has dramatically increased during the last few decades. Improved diagnostic standards, increased awareness, and increased screening initiatives are partly to blame for this increase, but environmental factors are also being investigated as possible causes. The rising incidence puts an increasing strain on families, healthcare systems, and educational institutions, underscoring the pressing need for improved support services, legislative changes, and inclusive social structures.



Figure 1: Autism Disorder

Co-occurring disorders such as attention deficit hyperactivity disorder (ADHD), anxiety, depression, epilepsy, and gastrointestinal issues are common in people with ASD. A multidisciplinary approach to therapy is required since these comorbidities make diagnosis and treatment even more difficult. In addition to being a scientific and medical issue, addressing ASD is also a public health and social responsibility.

Advancements in Research and Future Directions

The gut-brain axis, neurobiological anomalies, the genetic basis of ASD, and AI-powered diagnostic tools have all been the subject of ground-breaking research in recent years. Developments in computational models, functional MRI, and EEG have improved our knowledge of how the brain networks of people with ASD vary. Furthermore, the development of digital therapies and precision medicine is opening the door to more specialized and customized treatments.Even with these developments, there are still a number of unresolved issues about the precise pathophysiology of ASD and the best ways to treat it. With an emphasis on how these developments can improve clinical outcomes and the quality of life for people with ASD and their families, this review will critically examine the most recent research on ASD, its neurobiological foundations, innovative diagnostic techniques, and developing therapeutic approaches.

Obstacles in Intervention and Diagnosis

Even with significant progress in the study of ASD, early diagnosis is still difficult, especially in environments with limited resources. Conventional diagnostic techniques focus on behavioral tests, such the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS), which can be laborious and call for specific training. To increase early detection and accuracy, new technologies are being investigated, such as biomarker-based methods, eye-tracking devices, and machine learning algorithms. Since research has repeatedly demonstrated that prompt intervention improves social, cognitive, and behavioral outcomes, early diagnosis is essential. Since there is currently no known cure for ASD, the main goals of treatment are symptom management and enhanced adaptive functioning. Pharmacological treatments, are gaining traction, even if behavioral interventions like Applied Behavior Analysis (ABA), speech therapy, and occupational therapy continue to be the gold standard. Future ASD treatment may benefit from novel therapeutic modalities including gene therapy, neuromodulation (like transcranial magnetic stimulation), and digital therapies.

2. Literature Review:

The very complex neurodevelopmental disorder known as autism spectrum disorder (ASD) is typified by repetitive behaviours, limited interests, and ongoing social communication impairments. Numerous studies have been carried out in the last few decades to investigate its genesis, diagnosis, and available treatments. An in-depth examination of the neurological foundations, diagnostic developments, and new treatment approaches for ASD is the goal of this review of the literature.

With heritability estimates ranging from 50% to 90%, numerous studies have shown that ASD has a significant genetic component **(Tick et al., 2016**). Many risk genes linked to synapse function and neural development have been found using whole-exome sequencing and genome-wide association studies (GWAS) **(Satterstrom et al., 2020).**

Important discoveries in genetics include:

- **Genes that are synaptic:** Disrupted synaptic plasticity and connectivity are linked to mutations in genes such SHANK3, NRXN1, and CNTNAP2 **(Leblond et al., 2014).**
- **Chromosomal abnormalities:** ASD risk has been associated with copy number variants (CNVs) in 15q11–13, 16p11.2, and 22q11.2 **(Sanders et al., 2015).**
- **Rare de novo mutations:** Research suggests that the beginning of ASD may be influenced by spontaneous mutations in genes linked to neuronal migration and differentiation **(Iossifov et al., 2014).**

ASD is also significantly influenced by epigenetic changes, especially in reaction to environmental stressors during pregnancy, such as dietary deficits, exposure to pollutants, and maternal immunological activation (Loke et al., 2015). Without altering the genetic code, DNA methylation and histone changes can change gene expression, impacting brain development and vulnerability to ASD.

2.1. Changes in Neuroanatomical and Functional Connectivity

Developments in neuroimaging methods, such as diffusion tensor imaging (DTI) and functional magnetic resonance imaging (fMRI), have shed light on the anatomical and functional variations in the brain.

The key finding includes:

Early childhood cortical overgrowth: MRI scans show aberrant prefrontal and amygdala enlargement, which could be a factor in social cognition deficiencies **(Courchesne et al., 2011).**

Global brain communication is impacted by altered connection patterns in people with ASD, who show hyperconnectivity in local circuits but hypoconnectivity in long-range circuits **(Uddin et al., 2013).**

Neurotransmitter imbalances: According to **Cellot and Cherubini (2014),** ASD has been linked to impaired GABAergic inhibition and increased glutamatergic excitation, which can result in sensory hypersensitivity and cognitive rigidity.



Social impairment	Communication deficits	Repetitive behaviors
OFC – Orbitofrontal cortex ACC – Anterior cingulate cortex FG – Fusiform gyrus STS – Superior temporal sulcus A – Amygdala mirror neuron regions IFG – Inferior frontal gyrus PPC – Posterior parietal cortex	IFG- Inferior frontal gyrus (Broca's area) STS – Superior temporal sulcus SMA – Supplementary motor area BG – Basal ganglia SN – Substantia nigra Th – Thalamus PN – Pontine nuclei cerebellum	OFC – Orbitofrontal cortex ACC – Anterior cingulate cortex BG – Basal ganglia Th – Thalamus

Figure 2: Structural and functional abnormalities in ASD, including prefrontal cortex overgrowth, altered white matter connectivity, and amygdala enlargement, contribute to impairments in social cognition, communication, and sensory processing **(Courchesne et al., 2011; Uddin et al., 2013).**

2.2.Progress in the Diagnosis of ASD

2.2.1. Methods of Behavioural Diagnostics

The diagnosis of ASD has traditionally depended on behavioural observations and standardized evaluation instruments such as:

- Schedule for Autism Diagnostic Observations (ADOS)
- The revised Autism Diagnostic Interview (ADI-R)
- Scale of Social Responsiveness (SRS)
- Although these methods are still the gold standard, they take a lot of time, can be inconsistent, and can lead to a delayed diagnosis **(Lord et al., 2018).**

2.2.2. Neurophysiological and Biomarkers

The development of biomarker-based diagnostics has produced encouraging findings in:

- Neuroimaging biomarkers: Changes in brain connectivity and structure identified by EEG and fMRI **(Tye et al., 2018).**
- Metabolomic and proteomic indicators: Variations in lipid profiles, immunological markers, and amino acid metabolism in people with ASD **(West et al., 2019).**
- Peripheral blood indicators: inflammatory markers, oxytocin, and cytokines are all altered in people with ASD **(Goines & Van de Water, 2010).**

2.2.3. Machine Learning and Artificial Intelligence in the diagnosis of AD:

AI-driven diagnostic tools, such as eye-tracking systems that examine newborns' gaze fixation, have been developed as a result of recent developments in deep learning and artificial intelligence (AI) **(Jones & Klin,2013).** Automated voice analysis to identify children with ASD who have unusual vocal patterns **(Bone et al.,2015).**

AI-powered movement and facial expression analysis for early identification of ASD **(Thabtah, 2019).** Early intervention and improved diagnostic accuracy are possible with these tools.

2.3. Emerging Therapeutic Strategies for ASD

2.3.1. Pharmacological Interventions

A number of medications are used to treat comorbidities like irritability, anxiety, and repetitive behaviors, but none of them specifically address the basic symptoms of ASD:

Atypical antipsychotics, such as aripiprazole and risperidone, are approved to treat aggression and irritability in people with ASD **(McCracken et al., 2002).**

Although their effectiveness varies, selective serotonin reuptake inhibitors (SSRIs) are used to treat anxiety and repetitive behaviors **(Hollander et al., 2005).**

According to **Parker et al. (2017),** oxytocin-based therapies have the potential to improve social bonding and emotion identification.

2.3.2. Cognitive and Behavioral Interventions

The most effective treatment for ASD is still behavioral therapy, which includes:

- Positive behaviors and adaptive abilities are reinforced by Applied Behavior Analysis (ABA) **(Leaf et al., 2016).**
- According to **Wood et al. (2009),** cognitive behavioral therapy is useful for controlling anxiety and emotions.

2.3.3. The Gut-Brain Axis and Treatments Based on the Microbiome

According to recent studies, the pathogenesis of ASD may be influenced by abnormalities in the gut microbiota **(Kang et al., 2017).**

Therapeutic approaches consist of:

- Prebiotics and probiotics: Changing the gut flora to alleviate behavioral and gastrointestinal issues.
- According to early trials, fecal microbiota transplantation (FMT) helps people with ASD with their social behaviors and gut health **(Kang et al., 2019).**



Figure 3: Dysregulation of the gut-brain axis in SD involves microbial signals, immune activation, and vagal-endocrine pathways, influencing sensory processing, behavior, and stress response. Potential therapies include probiotics, diet, and fecal microbiota transplantation (FMT) **(Kang et al., 2017; Sharon et al., 2019).**

2.3.4. Digital Therapeutics and Neurotechnology

Novel treatments consist of:

- According to **Oberman et al. (2016**), transcranial magnetic stimulation (TMS) alters brain activity in networks involved in social cognition.
- People with ASD can improve their social abilities in safe settings by using virtual reality (VR)-based social training **(Wallace et al., 2017).**

3. CONCLUSION:

The neurodevelopmental disorder known as autism spectrum disorder (ASD) is extremely diverse and involves intricate interactions between genetic, epigenetic, neurological, and environmental variables. Understanding its genesis, improving diagnostic techniques, and developing effective treatment plans have all advanced significantly over the last few decades.

Many risk genes, especially those related to synapse function, neuronal migration, and neurotransmitter modulation, have been linked to ASD by genetic underpinnings research. The brain areas in charge of social cognition, executive function, and sensory processing have also shown structural and functional changes as a result of neuroimaging research. The multisystem nature of ASD is further highlighted by the involvement of immunological dysregulation and the gut-brain axis in its pathogenesis.

Early ASD detection is becoming more accurate and efficient thanks to diagnostic developments, especially the combination of artificial intelligence (AI) and machine learning. AI-powered facial recognition software, speech recognition software, and eye-tracking devices have the potential to provide quick, non-invasive, and objective screening techniques. Standardization, accessibility, and ethical issues are still problems, though.

Emerging therapeutic approaches, such as microbiome-targeted interventions, neuromodulation techniques (like TMS), and digital therapeutics (like virtual reality-based social training), offer new, customized treatment options, even though behavioral and pharmaceutical therapies remain the cornerstone of managing ASD. Precision medicine techniques that make use of genetic and biomarker data could result in individualized treatment plans catered to each patient's particular ASD profile.

Despite these developments, there are still a lot of unanswered questions about the variability of ASD, how to best treat it, and how to guarantee early intervention. In order to improve diagnosis, prognosis, and treatment outcomes for people with ASD, future research should concentrate on combining multi-omics data, neuroimaging, and AI-driven analytics.

4. Future Development

4.1. Developments in Biomarkers and Early Diagnosis

ASD requires early intervention, but because existing diagnostic techniques rely on subjective behavioral assessments, they frequently cause delays. Future advancements ought to concentrate on:

Validating genetic, metabolic, and neurophysiological markers to produce an extensive, non-invasive diagnostic panel is the next step in improving biomarker-based diagnoses.

Combining artificial intelligence (AI) with physiological and neuroimaging data: creating deep learning algorithms to examine fMRI, EEG, and eye-tracking data in order to detect ASD earlier and more accurately.

Accessible and portable screening tools: Developing mobile applications for ASD detection that can be used in low-resource environments and for home monitoring.

4.2. Methods of Precision and Personalized Medicine

Since ASD is a very diverse disorder, therapies must be customized for each person depending on their particular genetic and neurological makeup. Future studies ought to concentrate on:

Studies of genotype-phenotype correlation: Determining ASD subtypes to facilitate individualized treatment strategies.

Creating medications that target certain biochemical pathways, such as GABA-modulating medications for excitatory-inhibitory balance or oxytocin-based treatments for social cognitive impairments, is known as targeted pharmacological therapy.

Combination therapy approaches: Examining how behavioral, pharmaceutical, and neuromodulation strategies can work in concert.

4.3. Enhancements to Accessibility and Policy

Policies must encourage the following in order to guarantee that developments in ASD research result in practical advantages:

Programs for universal screening to detect ASD early. More money allocated to interdisciplinary and customized research, enhanced availability of cutting-edge treatments in environments with limited resources.

4.4. Final Outlook :

A multidisciplinary, precision-medicine strategy combining behavioral therapies, microbiome science, neuroimaging, AI, and genetics holds the key to the future of ASD research and treatment. It will be essential to close the gap between biological research and practical applications to guarantee prompt diagnosis, successful therapies, and enhanced quality of life for people with ASD.

5. References:

[1] Tick, B., Bolton, P., Happé, F., Rutter, M., & Rijsdijk, F. (2016). Heritability of autism spectrum disorders: A meta-analysis of twin studies. *Journal of Child Psychology and Psychiatry*, 57(5), 585–595.

[2] Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J. Y., Peng, M., Collins, R., Grove, J., Klei, L., Stevens, C., & Reichert, J. (2020). Large-scale exome sequencing study implicates both developmental

and functional changes in the genetics of autism. *Cell*, 180(3), 568–584.

[3] Sanders, S. J., He, X., Willsey, A. J., Ercan-Sencicek, A. G., Samocha, K. E., Cicek, A. E., Murtha, M. T., Bal, V. H., Bishop, S. L., Dong, S., & Goldberg, A. P. (2015). Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. *Neuron*, 87(6), 1215–1233.

[4] Iossifov, I., O'Roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., Stessman, H. A. F., Witherspoon, K. T., Vives, L., Patterson, K. E., & Smith, J. D. (2014). The contribution of de novo coding mutations to autism spectrum disorder. *Nature*, 515(7526), 216–221.

[5] Loke, Y. J., Hannan, A. J., & Craig, J. M. (2015). The role of epigenetic change in autism spectrum disorders. *Frontiers in Neurology*, 6, 107.

[6] Ecker, C., Bookheimer, S. Y., & Murphy, D. G. (2015). Neuroimaging in autism spectrum disorder: Brain structure and function across the lifespan. *The Lancet Neurology*, 14(11), 1121–1134.

[7] Uddin, L. Q., Supekar, K., Lynch, C. J., Khouzam, A., Phillips, J., Feinstein, C., & Menon, V. (2013). Salience network-based classification and prediction of symptom severity in children with autism. *JAMA Psychiatry*, 70(8), 869–879.

[8] Cellot, G., & Cherubini, E. (2014). GABAergic signaling as therapeutic target for autism spectrum disorders. *Frontiers in Pediatrics*, 2, 70.

[9] Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E., Jones, R. M., Pickles, A., State, M. W., & Taylor, J. L. (2018). Autism spectrum disorder. *Nature Reviews Disease Primers*, 4, 5.

[10] Tye, C., Bolton, P., & Asherson, P. (2018). Neurophysiological biomarkers of autism spectrum disorder: Current state and future developments. *Developmental Medicine & Child Neurology*, 60(2), 143–155.

[11] Jones, W., & Klin, A. (2013). Attention to eyes is present but in decline in 2–6-month-old infants later diagnosed with autism. *Nature*, 504(7480), 427–431.

[12] Bone, D., Lee, C. C., Black, M. P., Williams, M. E., Lee, S., Levitt, P., & Narayanan, S. (2015). The psychologist as an interlocutor in autism spectrum disorder assessment: Insights from a study of spontaneous prosody. *Journal of Speech, Language, and Hearing Research*, 58(4), 1166–1180.

[13] Thabtah, F. (2019). Machine learning in autistic spectrum disorder behavioral research: A review and ways forward. *Informatics for Health and Social Care*, 44(3), 278–297.

[14] McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., & Koenig, K. (2002). Risperidone in children with autism and serious behavioral problems. *New England Journal of Medicine*, 347(5), 314–321.

[15] Hollander, E., Phillips, A. T., & Yeh, C. C. (2005). Targeted treatments for symptom domains in child and adolescent autism. *The Lancet*, 4(12), 840–846.

[16] Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., & Carson, D. S. (2017). Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. *Proceedings of the National Academy of Sciences*, 114(30), 8119–8124.

[17] Kang, D. W., Park, J. G., Ilhan, Z. E., Wallstrom, G., Labaer, J., Adams, J. B., & Krajmalnik-Brown, R. (2017). Reduced incidence of autism spectrum disorder symptoms in children treated with microbiota transfer therapy. *Scientific Reports*, 9, 5821.

[18] Oberman, L. M., Rotenberg, A., & Pascual-Leone, A. (2016). Modulation of cortical plasticity in autism spectrum disorder: Theoretical model and therapeutic implications. *Progress in Neurobiology*, 134, 156–170.

[19] Wallace, S., Parsons, S., & Bailey, A. (2017). Virtual reality in autism spectrum disorder: A review of technology, experimental design, and clinical findings. *International Journal of Developmental Neuroscience*, 57, 26–37.